The clinical significance of a new monoclonal antibody defined antigen CA195 as a tumor marker in colorectal cancer.
We evaluated a new monoclonal antibody defined antigen CA195 as a tumor marker in patients with colorectal adenocarcinoma and compared the results with CA19-9 and carcinoembryonic antigen (CEA). This study included 37 patients with colorectal adenocarcinoma, 118 healthy subjects, 20 hepatitis with or without jaundice, and 20 duodenal ulcer with or without smoking habits. The average concentration of CA195 in serum from 118 healthy subjects is 5.80 +/- 6.83 U/ml. In the 37 patients with colorectal adenocarcinoma, 13 had elevated levels (greater than 30 U/ml) of CA195 (35%), 10 had elevated levels (greater than 37 U/ml) of CA19-9 (27%), and 18 and elevated levels (greater than 5 ng/ml) of CEA (48%). The sensitivity of CA195 is correlated well with the extent of the malignancy, 9% in Duke's stage A and B, and 79% in advanced stage C and D. Although the sensitivity of CA195 is less than CEA (35% vs. 48%), this difference is not statistically significant scaled (P greater than 0.05). Combined use CA195 with CEA can increase detecting rate from 48% (CEA alone) to 59%. CA-195 level may be elevated in some patients with hepatocellular disease, but its level is not affected by smoking. Therefore CA-195 can be applied as complementary tumor marker in colorectal cancer.